These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24192167)

  • 1. Structural and docking studies of potent ethionamide boosters.
    Tatum NJ; Villemagne B; Willand N; Deprez B; Liebeschuetz JW; Baulard AR; Pohl E
    Acta Crystallogr C; 2013 Nov; 69(Pt 11):1243-50. PubMed ID: 24192167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.
    Flipo M; Desroses M; Lecat-Guillet N; Dirié B; Carette X; Leroux F; Piveteau C; Demirkaya F; Lens Z; Rucktooa P; Villeret V; Christophe T; Jeon HK; Locht C; Brodin P; Déprez B; Baulard AR; Willand N
    J Med Chem; 2011 Apr; 54(8):2994-3010. PubMed ID: 21417236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
    Flipo M; Desroses M; Lecat-Guillet N; Villemagne B; Blondiaux N; Leroux F; Piveteau C; Mathys V; Flament MP; Siepmann J; Villeret V; Wohlkönig A; Wintjens R; Soror SH; Christophe T; Jeon HK; Locht C; Brodin P; Déprez B; Baulard AR; Willand N
    J Med Chem; 2012 Jan; 55(1):68-83. PubMed ID: 22098589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator.
    Engohang-Ndong J; Baillat D; Aumercier M; Bellefontaine F; Besra GS; Locht C; Baulard AR
    Mol Microbiol; 2004 Jan; 51(1):175-88. PubMed ID: 14651620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-Based Optimized EthR Inhibitors with
    Villemagne B; Machelart A; Tran NC; Flipo M; Moune M; Leroux F; Piveteau C; Wohlkönig A; Wintjens R; Li X; Gref R; Brodin P; Deprez B; Baulard AR; Willand N
    ACS Infect Dis; 2020 Mar; 6(3):366-378. PubMed ID: 32011115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
    Flipo M; Willand N; Lecat-Guillet N; Hounsou C; Desroses M; Leroux F; Lens Z; Villeret V; Wohlkönig A; Wintjens R; Christophe T; Kyoung Jeon H; Locht C; Brodin P; Baulard AR; Déprez B
    J Med Chem; 2012 Jul; 55(14):6391-402. PubMed ID: 22738293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
    Prieri M; Frita R; Probst N; Sournia-Saquet A; Bourotte M; Déprez B; Baulard AR; Willand N
    Eur J Med Chem; 2018 Nov; 159():35-46. PubMed ID: 30268015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of the TetR/CamR family repressor Mycobacterium tuberculosis EthR implicated in ethionamide resistance.
    Dover LG; Corsino PE; Daniels IR; Cocklin SL; Tatituri V; Besra GS; Fütterer K
    J Mol Biol; 2004 Jul; 340(5):1095-105. PubMed ID: 15236969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into mechanisms of induction and ligands recognition in the transcriptional repressor EthR from Mycobacterium tuberculosis.
    Frénois F; Baulard AR; Villeret V
    Tuberculosis (Edinb); 2006 Mar; 86(2):110-4. PubMed ID: 16243584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
    Choi J; Park SJ; Jee JG
    Eur J Med Chem; 2015 Dec; 106():157-66. PubMed ID: 26544630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic di-GMP regulates Mycobacterium tuberculosis resistance to ethionamide.
    Zhang HN; Xu ZW; Jiang HW; Wu FL; He X; Liu Y; Guo SJ; Li Y; Bi LJ; Deng JY; Zhang XE; Tao SC
    Sci Rep; 2017 Jul; 7(1):5860. PubMed ID: 28725053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.
    Nikiforov PO; Surade S; Blaszczyk M; Delorme V; Brodin P; Baulard AR; Blundell TL; Abell C
    Org Biomol Chem; 2016 Feb; 14(7):2318-26. PubMed ID: 26806381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New active leads for tuberculosis booster drugs by structure-based drug discovery.
    Tatum NJ; Liebeschuetz JW; Cole JC; Frita R; Herledan A; Baulard AR; Willand N; Pohl E
    Org Biomol Chem; 2017 Dec; 15(48):10245-10255. PubMed ID: 29182187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baeyer-Villiger Monooxygenases EthA and MymA Are Required for Activation of Replicating and Non-replicating Mycobacterium tuberculosis Inhibitors.
    Grant SS; Wellington S; Kawate T; Desjardins CA; Silvis MR; Wivagg C; Thompson M; Gordon K; Kazyanskaya E; Nietupski R; Haseley N; Iwase N; Earl AM; Fitzgerald M; Hung DT
    Cell Chem Biol; 2016 Jun; 23(6):666-77. PubMed ID: 27321573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.
    Nikiforov PO; Blaszczyk M; Surade S; Boshoff HI; Sajid A; Delorme V; Deboosere N; Brodin P; Baulard AR; Barry CE; Blundell TL; Abell C
    ACS Chem Biol; 2017 May; 12(5):1390-1396. PubMed ID: 28314097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis.
    Frénois F; Engohang-Ndong J; Locht C; Baulard AR; Villeret V
    Mol Cell; 2004 Oct; 16(2):301-7. PubMed ID: 15494316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of the antituberculosis drug ethionamide.
    Vale N; Gomes P; Santos HA
    Curr Drug Metab; 2013 Jan; 14(1):151-8. PubMed ID: 23215813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1).
    Pechalrieu D; Lopez M
    Expert Opin Ther Pat; 2015 Jun; 25(6):729-35. PubMed ID: 25752488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.
    Grau T; Selchow P; Tigges M; Burri R; Gitzinger M; Böttger EC; Fussenegger M; Sander P
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1142-5. PubMed ID: 22106218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.
    Brossier F; Veziris N; Truffot-Pernot C; Jarlier V; Sougakoff W
    Antimicrob Agents Chemother; 2011 Jan; 55(1):355-60. PubMed ID: 20974869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.